

Vunakizumab: Adis Evaluation

Clinical Considerations

- Novel anti-IL17A humanised IgG1/k monoclonal antibody
- Increases the proportion of patients who achieve complete or near complete clearance of chronic plaque psoriasis symptoms and lesions by week 12
- Sustains treatment response in the majority of patients through to week 52
- Generally well tolerated

Plain Language Summary

Background and rationale

- Chronic plaque psoriasis is an inflammatory skin condition that can cause a substantial reduction in a patient's quality of life
- Vunakizumab (安达静®) is a new treatment that blocks one of the key inflammatory cascades that leads to chronic plaque psoriasis
- It is approved in China for adults with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy

Clinical findings

- In a pivotal phase 3 study, complete or near complete clearance of chronic plaque psoriasis symptoms and lesions occurred significantly more frequently in vunakizumab than placebo recipients at week 12 of treatment, and treatment response was maintained in the majority of vunakizumab recipients through to week 52
- Vunakizumab was also generally well tolerated through to week 52

Conclusion

Vunakizumab represents a new and efficacious treatment option for patients with moderate-to-severe chronic plaque psoriasis.

This plain language summary represents the opinions of the author. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. © Springer Nature Switzerland AG 2026.